비신생혈관성 AMD에 이차적으로 발생하는 비중심포 지형 위축증에 대한 GAL-101, 2% 안과 용액의 2상 효능 및 안전성 연구 (eDREAM)
비신생혈관 연령에 따른 비중심와 지리 위축 환자에서 GAL-101, 2% 안과 용액의 효능 및 안전성을 조사하기 위한 제2상, 이중 마스크, 무작위, 다기관, 병렬 그룹, 위약 대조 연구- 관련 황반변성: EDREAM 연구
Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensitive cells, called photoreceptors. That part of the retina can no longer see. Atrophy begins as a small spot in the retina distant from the fovea which is the part of the retina responsible for sharp central vision. The GA grows, and when it reaches the fovea, vision is severely diminished, and details cannot be seen anymore. The purpose of the eDREAM study is to understand if GAL-101 can slow the growth of GA and prevent it from reaching the fovea. GAL-101 is given as eyedrops. eDREAM patients will administer study eyedrops every day. Patients will be assigned by chance (randomly) to receive either eye-drops that contain the new medication, GAL-101, or eyedrops without the active drug (Placebo). Neither patients nor doctors will know which treatment was assigned to each patient until the end of the study.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
In this study, if both eyes qualify for the study, the eye with the better BCVA will be defined as the study eye. If both eyes qualify for the study and have identical BCVA, then the eye with higher baseline peripheral retinal degenerations (PRD) will be defined as the study eye. If baseline PRD is identical, then the right eye (OD) will be defined as the study eye. Only the study eye will be dosed with the Investigation Medicinal Product (IMP).
During visits, patients will administer 3 applications of 1 drop of GAL-101 or a matching Placebo that does not contain the active pharmaceutical ingredient (API) at 5-minute intervals (i.e., 1st application, wait 5 minutes, 2nd application, wait 5 minutes, 3rd application), under the supervision of trained and authorized study personnel. In between visits, patients will be instructed to administer 2 applications of 1 drop at 5-minute intervals once a day.
The study will be comprised of a 12- to 24-month treatment period determined individually according to patients' overall placement in global study randomization. All patients will participate at least 12 months of treatment. The visit schedule includes the following: Screening visits (Visit 1a and 1b) for image capture and confirmation of study eligibility by a reading center; Baseline/Randomization/Day 1 (Visit 2); a phone call at 2 weeks; and on-treatment clinic visits for safety and efficacy evaluations at 1 month, 3 months, 6 months, 9 months, and 12 months. Patients will continue to attend on-treatment clinic visits at 3-month intervals after 12 months until the last patient randomized in the study has completed 12 months of study treatment.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Galimedix Inc. c/o Imperial CRS, MD
- 전화번호: +1 (301) 9179191
- 이메일: info@galimedix.com
연구 연락처 백업
- 이름: Luciana Summo, PhD
- 이메일: info@galimedix.com
연구 장소
-
-
-
Tbilisi, 그루지야, 0162
- 모병
- Akhali Mzera Limited
-
연락하다:
- Revaz Bezarashvili
- 전화번호: (+995) 555 55 54 82
- 이메일: rezieye@gmail.com
-
수석 연구원:
- Shalva Skhirtladze, MD
-
Tbilisi, 그루지야, 0186
- 모병
- Caucasus Medical Centre LLC
-
연락하다:
- Sopio Tsiklauri, MD
- 전화번호: (+995) 595 974 774
- 이메일: soffia01@yahoo.com
-
수석 연구원:
- Mikheil Omiadze, MD, PhD
-
-
-
-
-
Bonn, 독일, 53127
- 모병
- Universitäts-Augenklinik Bonn
-
수석 연구원:
- Kristina Pfau, MD
-
연락하다:
- Joanna Czauderna Study Coordinator
- 전화번호: 0228 287-11493
- 이메일: Joanna.Czauderna@ukbonn.de
-
Freiburg im Breisgau, 독일, 79106
- 모병
- Universitätsklinikum Freiburg Klinik für Augenheilkunde
-
수석 연구원:
- Hansjuergen Agostini, MD
-
연락하다:
- Christine Kremer
- 전화번호: +49 761 270 40231
- 이메일: christine.kremer@uniklinik-freiburg.de
-
Hanover, 독일, 30625
- 모병
- Medizinische Hochschule Hannover Augenklinik
-
연락하다:
- Irene Oluwatoba-Popoola
- 이메일: Oluwatoba-popoola.irene@mh-hannover.de
-
수석 연구원:
- Ekaterina Sokolenko, MD
-
Neubrandenburg, 독일, 17036
- 모병
- Dietrich Bonhoeffer Klinikum
-
연락하다:
- Ulrike Holland
- 전화번호: +49 395 775 13427
- 이메일: aug-st2@dbknb.de
-
수석 연구원:
- Christian Brinkmann, MD
-
Tübingen, 독일, 72076
- 모병
- Universitätsklinikum Tübingen, Department für Augenheilkunde.
-
연락하다:
- Angela Geiger
- 이메일: Felix.Reichel@med.uni-tuebingen.de
-
수석 연구원:
- Felix Reichel, MD
-
Ulm, 독일, 89075
- 아직 모집하지 않음
- UNIVERSITÄTSKLINIKUM ULM Klinik für Augenheilkunde
-
연락하다:
- Julia Ciboci
- 이메일: Julia.Ciboci@uniklinik-ulm.de
-
수석 연구원:
- Armin Wolf, MD
-
-
-
-
California
-
Beverly Hills, California, 미국, 90211
- 모병
- Retina-Vitreous Associates Medical Group
-
수석 연구원:
- David Boyer, MD
-
연락하다:
- Rahul Araza
- 전화번호: 3 (310) 289-2478
- 이메일: raraza@laretina.com
-
Walnut Creek, California, 미국, 94598
- 모병
- Bay Area Retina Associates
-
수석 연구원:
- Roger Goldberg, MD
-
연락하다:
- Karrie Padilla
- 전화번호: 925-265-4146
- 이메일: kpadilla@bayarearetina.com
-
-
Maryland
-
Hagerstown, Maryland, 미국, 21740
- 정지된
- Cumberland Valley Retina Consultants
-
-
-
-
-
Yerevan, 아르메니아, 0048
- 모병
- Ophthalmological Center After S.V. Malayan
-
연락하다:
- Ani Babayan
- 전화번호: +37494909990
- 이메일: babayanani88@yahoo.com
-
수석 연구원:
- Lilit Voskanyan, MD, PhD
-
-
-
-
-
Kildare, 아일랜드, W91 W535
- 모병
- UPMC Kildare Hospital Prosperous Rd Clane, Kildare Ireland
-
수석 연구원:
- Eugene Ng, MD
-
연락하다:
- Hiella Akhundova
- 전화번호: +353 89 411 2119
- 이메일: hiella.a@ioes.ie
-
Waterford, 아일랜드, X91 DH9W
- 모병
- Institute of Eye Surgery (IOES Waterford)
-
수석 연구원:
- Eugene Ng, MD
-
연락하다:
- Emmanuel Ankamah
- 전화번호: +353 89 411 2119
- 이메일: emmanuel.a@ioes.ie
-
-
-
-
-
Jerusalem, 이스라엘, 9112001
- 모병
- Hadassah Medical Center
-
연락하다:
- Michal Shpigel
- 전화번호: 972-54-4575921
- 이메일: smichal@hadassah.org.il
-
수석 연구원:
- Tareq Jaouni, MD
-
Tel Aviv, 이스라엘, 6423906
- 모병
- Tel Aviv Medical Center
-
연락하다:
- Marina Gordon
- 전화번호: 972-3-6947371
- 이메일: marinago@tlvmc.gov.il
-
수석 연구원:
- Omer Trivizki, MD
-
-
-
-
Milano
-
Milan, Milano, 이탈리아, 20123
- 모병
- Medical Retina & Imaging Unit, IRCCS MultiMedica, Ospedale San Giuseppe
-
연락하다:
- Mara Cattaneo Study Coordinator
- 이메일: mara.cattaneo@multimedica.it
-
수석 연구원:
- Stela Vujosevic, MD
-
Milan, Milano, 이탈리아, 20132
- 모병
- Unità di Oculistica, IRCCS Ospedale San Raffaele
-
연락하다:
- Adelaide Pina Study Coordinator
- 전화번호: 0226433545
- 이메일: pina.adelaide@hsr.it
-
수석 연구원:
- Francesco Bandello, MD
-
-
Roma
-
Roma, Roma, 이탈리아, 00184
- 모병
- UOS Retina Medica, P.O. Britannico, IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia
-
연락하다:
- Ilaria Casale, Dr
- 이메일: ilaria.casale@fondazionebietti.it
-
수석 연구원:
- Mariacristina Parravanno, MD
-
-
-
-
-
Bordeaux, 프랑스, 33000
- 모병
- Centre Rétine Gallien
-
연락하다:
- Manon Demeurs
- 전화번호: 33 (5) 56 11 32 25
- 이메일: arc@retinegallien.com
-
수석 연구원:
- Eric Fourmaux, MD
-
Lyon, 프랑스, 69317
- 모병
- Hopital de La Croix-Rousse Service D'Ophtalmologie Groupement Hospitalier Nord Hospices Civils de Lyon
-
연락하다:
- Roxane Bai
- 전화번호: +33 (0)4 26 73 27 02
- 이메일: roxane.bai@chu-lyon.fr
-
수석 연구원:
- Laurent KODJIKIAN, MD
-
Marseille, 프랑스, 13008
- 모병
- Centre Monticelli Paradis d'Ophtalmologie
-
연락하다:
- Agné Devin Dr.
- 전화번호: 049116 05 84
- 이메일: agne.retine@gmail.com
-
수석 연구원:
- François Devin, MD
-
Paris, 프랑스, 75006
- 모병
- Centre Ophtalmologique Odéon
-
연락하다:
- Sumeyye OZALTUN
- 이메일: ozalt.sumeyye@gmail.com
-
연락하다:
- Favard, MD
-
수석 연구원:
- Catherine Favard, MD
-
Tours, 프랑스, 37540
- 모병
- Centre médico-chirurgical de Touraine
-
연락하다:
- Sarah Van Herreweghe
- 전화번호: 33 (0)2 47 64 67 27
- 이메일: svanherreweghe6@gmail.com
-
수석 연구원:
- Sam Razavi, MD
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
≥55 years of age
-
Willing and able to provide written informed consent
-
Willing and able to comply with the study schedule and study assessments
-
Able to successfully administer ophthalmic solution or have an appropriate designee (e.g., family member, health care professional) who can administer ophthalmic solution
-
BCVA of ≥50 letters in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS) chart (i.e., 20/100 Snellen equivalent). Criterion will be confirmed at Baseline
-
Refractive error between +3 and -6 diopters spherical equivalent in the study eye
-
Sufficiently clear ocular media and adequate pupillary dilation to permit quality fundus imaging of the study eye, in the opinion of the Investigator. Criterion will be confirmed at Baseline
-
Diagnosed with non-foveal GA secondary to non-neovascular AMD in the study eye, as confirmed by the reading center
- Well-delineated cumulative GA area between 1.25 and 12.0 mm2
- If GA is multifocal, at least 1 lesion ≥1.25 mm2
- GA lesions must be located outside a ≥100 µm radius from the center point of the fovea (i.e., this area must have intact retinal pigment epithelium [RPE] and outer retina)
- GA lesions must be located (partially or wholly) within a 2000 µm radius from the center point of the fovea
- GA lesions must be completely located within FAF imaging field (field 2 to 30-degree image centered on the fovea). GA lesion borders must be >300 µm from image edges
- GA lesions must be >300 µm from the optic disc and/or peripapillary atrophy
- Area of PRD must be cumulatively between 7.25 and 25.0 mm2
Exclusion Criteria:
-
Presence or history of choroidal neovascularization (CNV). Criterion will be confirmed at Baseline
-
History of laser therapy in the macular region, regardless of indication
-
History of herpes zoster
-
Ophthalmic disease or condition that requires or is likely to require surgery during the study period
-
GA with cumulative area <1.25 mm2
-
Any GA lesion within 100 µm radius from the center point of the fovea
-
Axial length >26 mm
-
Any ocular disease or condition other than non-neovascular AMD that may, in the opinion of the Investigator, interfere with study assessments, patient adherence to the study schedule, or interpretation of study data (e.g., epiretinal membrane, macular hole, glaucomatous optic neuropathy, etc.)
-
Intraocular surgery (including cataract extraction and crystalline lens replacement) within 3 months before Visit 1a or yttrium aluminum garnet (YAG) surgery within 2 months before Visit 1a, or planned either during the study period
-
Use of pegcetacoplan or avacincaptad pegol within 6 months before Visit 1a, or planned use during the study period
-
Use of any prescription or over-the-counter ophthalmic medication within 1 month before Visit 1a or planned use during the study period
-
Use of rigid contact lenses within 1 month before Visit 1a or planned use during the study period
Non-study Eye:
-
BCVA of <5 letters using ETDRS chart (i.e., 20/800 Snellen equivalent)
Either Eye:
-
History of uveitis
-
GA secondary to any condition other than non-neovascular AMD
-
History of active ocular infection or inflammation within 3 months before Visit 1a or Baseline. Criterion will be confirmed at Baseline
-
Underwent investigational treatment for AMD within 6 months before Visit 1a
General Exclusion Criteria:
-
History of therapeutic radiation to the cranium
-
Known allergy or hypersensitivity to the investigational medicinal product (IMP) or any of its excipients
-
History of malignant disease
-
Use of hydroxychloroquine within 1 month before Visit 1a, or planned use during the study period
-
Participated or plan to participate in any other IMP study within 1 month before Visit 1a or during the study period
-
Use of lutein >10 mg per day or zeaxanthin >2 mg per day within 1 month before Visit 1a, or planned use during the study period
-
Any medical condition (including mental), in the opinion of the Investigator, that could interfere with study assessments, patient adherence to the study schedule, or interpretation of study data
-
Screening laboratory values, in the opinion of the Investigator, that make the patient unsuitable for study participation
-
Pregnant, nursing, or planning a pregnancy during the study. Criterion will be confirmed at Baseline
-
Unwilling or unable to use an acceptable method of contraception throughout the study if a woman of childbearing potential (WOCBP) or if a sexual partner of a WOCBP
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: GAL-101 ophthalmic solution
Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval |
Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval |
|
위약 비교기: Placebo
Patient will apply daily 2 eye drops ofPlacebo at 5 minutes interval |
Patient will apply daily 2 eye drops of Placebo at 5 minutes interval |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in GA lesion size.
기간: From baseline to last on-treatment visit (48 up to 96 weeks)
|
Comparison between groups of annual rate of change in the area of GA as measured by fundus autofluorescence (FAF). |
From baseline to last on-treatment visit (48 up to 96 weeks)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in photoreceptor degeneration (PRD) in eyes with GA
기간: From baseline to last on-treatment visit (48 up to 96 weeks)
|
Comparison between groups of annual rate of change in the area of PRD as measured by optical coherence tomography (OCT) |
From baseline to last on-treatment visit (48 up to 96 weeks)
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- GAL-101-C0201
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .